Prophylaxis for covid-19: living systematic review and network meta-analysis
Preprint
Abstract
Objective: To determine and compare the effects of drug prophylaxis on severe acute respiratory syndrome coronavirus virus 2 (SARS-CoV-2) infection and coronavirus disease 2019 (covid-19). Design: Living systematic review and network meta-analysis. Data sources: WHO covid-19 database, a comprehensive multilingual source of global covid-19 literature to 19 January 2021, and six additional Chinese databases to 20 January 2021. Study selection: Randomized trials in which people at risk of covid-19 were randomized to drug prophylaxis or no prophylaxis (standard care or placebo). Pairs of reviewers independently screened potentially eligible articles. Methods: After duplicate data abstraction, we conducted random-effects bayesian network meta-analysis. We assessed risk of bias of the included studies using a modification of the Cochrane risk of bias 2.0 tool and assessed the certainty of the evidence using the grading of recommendations assessment, development and evaluation (GRADE) approach. Results: The first iteration of this living network meta-analysis includes nine randomized trials – six addressing hydroxychloroquine (6,059 participants), one addressing ivermectin combined with iota-carrageenan (234 participants) and two addressing ivermectin alone (540 participants), all compared to standard care or placebo. Hydroxychloroquine has no important effect on admission to hospital (risk difference (RD) 1 fewer per 1,000, 95% credible interval (CrI) 3 fewer to 4 more, high certainty) or mortality (RD 1 fewer per 1,000, 95% CrI 2 fewer to 3 more, high certainty). Hydroxychloroquine probably has no important effect on laboratory-confirmed infection (RD 2 more per 1,000, 95% CrI 18 fewer to 28 more, moderate certainty), probably increases adverse effects leading to drug discontinuation (RD 19 more per 1,000, 95% CrI 1 fewer to 70 more, moderate certainty) and may have no important effect on suspected, probable or laboratory-confirmed infection (RD 15 fewer per 1,000, 95% CrI 64 fewer to 41 more, low certainty). Due to serious risk of bias and very serious imprecision – and thus very low certainty evidence, the effects of ivermectin combined with iota-carrageenan on laboratory-confirmed infection (RD 52 fewer per 1,000, 95% CrI 58 fewer to 37 fewer), and ivermectin alone on laboratory-confirmed infection (RD 50 fewer per 1,000, 95% CrI 59 fewer to 16 fewer) and suspected, probable or laboratory-confirmed infection (RD 159 fewer per 1,000, 95% CrI 165 fewer to 144 fewer) remain uncertain. Conclusion: Hydroxychloroquine prophylaxis does not have an important effect on hospital admission and mortality, probably increases adverse effects, and probably does not have an important effect on laboratory-confirmed SARS-CoV-2 infection. Because of serious risk of bias and very serious imprecision, we are highly uncertain whether ivermectin combined with iota-carrageenan and ivermectin alone reduce the risk of SARS-CoV-2 infection. Systematic review registration: This review was not registered. The protocol established a priori is included as a supplement. Funding: This study was supported by the Canadian Institutes of Health Research (grant CIHR-IRSC:0579001321). Readers’ note: This article is a living systematic review that will be updated to reflect emerging evidence. Updates may occur for up to two years from the date of original publication.Keywords
All Related Versions
- Published version: BMJ, 373, n949.
This publication has 26 references indexed in Scilit:
- Evidence-based medicine in times of crisisJournal of Clinical Epidemiology, 2020
- A living WHO guideline on drugs for covid-19 (2020-2023)BMJ, 2020
- Drug treatments for covid-19: living systematic review and network meta-analysisBMJ, 2020
- Remdesivir for severe covid-19: a clinical practice guidelineBMJ, 2020
- Machine learning for identifying Randomized Controlled Trials: An evaluation and practitioner's guideResearch Synthesis Methods, 2018
- Living systematic review: 1. Introduction—the why, what, when, and howJournal of Clinical Epidemiology, 2017
- Introduction toBMJRapid RecommendationsBMJ, 2016
- Living cumulative network meta-analysis to reduce waste in research: A paradigmatic shift for systematic reviews?BMC Medicine, 2016
- The PRISMA Extension Statement for Reporting of Systematic Reviews Incorporating Network Meta-analyses of Health Care Interventions: Checklist and ExplanationsAnnals of Internal Medicine, 2015
- A GRADE Working Group approach for rating the quality of treatment effect estimates from network meta-analysisBMJ, 2014